Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

Bibliographic Details
Main Authors:	Roth, D A, Thompson, A, Tang, Y, Hammer, A E, Molta, C T, Gordon, D
Format:	Online
Language:	English
Published:	SAGE Publications 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785993/

Similar Items

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
by: Collins, Christopher E, et al.
Published: (2006)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
by: Stohl, William
Published: (2003)

Belimumab in systemic lupus erythematosus
by: Vilas-Boas, Andreia, et al.
Published: (2015)

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Published: (2012)

Belimumab in Systemic Lupus Erythematosus
by: Srivastava, Ankita
Published: (2016)

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
by: López, Patricia, et al.
Published: (2016)

The current status of targeting BAFF/BLyS for autoimmune diseases
by: Ramanujam, Meera, et al.
Published: (2004)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
by: van Vollenhoven, Ronald F, et al.
Published: (2012)

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
by: Jagessar, S. Anwar, et al.
Published: (2012)

G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
by: Scapini, Patrizia, et al.
Published: (2003)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
by: van Vollenhoven, Ronald F., et al.
Published: (2016)

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells
by: Zhu, Jing, et al.
Published: (2012)

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin
by: Parameswaran, Reshmi, et al.
Published: (2012)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
by: Schwarting, A, et al.
Published: (2016)

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
by: Yapa, S Wickramaratne Senarath, et al.
Published: (2016)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
by: Sheikh, Saira Z., et al.
Published: (2016)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
by: Collins, C E, et al.
Published: (2016)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
by: Dubey, Ashok K., et al.
Published: (2011)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
by: Jagessar, S. Anwar, et al.
Published: (2012)

Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
by: Luster, Troy A., et al.
Published: (2012)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
by: Kyrtsonis, Marie-Christine, et al.
Published: (2014)

Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells
by: Sindhava, Vishal J., et al.
Published: (2013)

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation
by: Goenka, Radhika, et al.
Published: (2014)

B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance
by: Müller, Nike, et al.
Published: (2014)

New treatment options for lupus – a focus on belimumab
by: Chiche, Laurent, et al.
Published: (2012)

Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis
by: Kandala, Ngianga-Bakwin, et al.
Published: (2013)

Blood B Lymphocyte Stimulator (BLyS)/BAFF levels may reflect natural immunity to HIV in highly exposed uninfected Beninese Commercial Sex Workers
by: Sabourin-Poirier, Catherine, et al.
Published: (2016)

High Expression Levels of BLyS/BAFF by Blood Dendritic Cells and Granulocytes Are Associated with B-cell dysregulation in SIV-Infected Rhesus Macaques
by: Poudrier, Johanne, et al.
Published: (2015)

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis
by: Pierotti, Francesca, et al.
Published: (2015)

A Rare Case of Prototheca Algaemia in a Patient with Systemic Lupus Erythematosus and Recent Belimumab Infusion
by: Mejia-Otero, Carolina, et al.
Published: (2012)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
by: Specchia, Maria Lucia, et al.
Published: (2014)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
by: Yamada, Masanori, et al.
Published: (2013)

Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS)
by: Gor, Dennis O, et al.
Published: (2011)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
by: Bruce, I N, et al.
Published: (2016)

Elevated levels of soluble intercellular adhesion molecule -1 in systemic lupus erythematosus
by: Kljukvina, N, et al.
Published: (2001)

Healthcare Utilization and Costs of Systemic Lupus Erythematosus in Medicaid
by: Kan, Hong J., et al.
Published: (2013)

Real life experience on the effect of Belimumab in patients with active systemic lupus
by: Scheinberg, Morton, et al.
Published: (2014)

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
by: Frieri, Marianne, et al.
Published: (2015)

Clinical response to belimumab in academic clinical practices
by: Reddy, Arthi, et al.
Published: (2014)

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study
by: Schwarting, Andreas, et al.
Published: (2016)